| Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. | |
| | |
MedLine Citation:
|
PMID: 20564136 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The current study was performed to compare the clinical outcomes and toxicity in patients treated with postoperative chemoradiotherapy for gastric cancer using intensity-modulated radiotherapy (IMRT) versus 3-dimensional conformal radiotherapy (3D CRT). METHODS: Fifty-seven patients with gastric or gastroesophageal junction cancer were treated postoperatively: 26 with 3D CRT and 31 with IMRT. Concurrent chemotherapy was capecitabine (n=31), 5-fluorouracil (5-FU) (n=25), or none (n=1). The median radiation dose was 45 Gy. Dose volume histogram parameters for kidney and liver were compared between treatment groups. RESULTS: The 2-year overall survival rates for 3D CRT versus IMRT were 51% and 65%, respectively (P=.5). Four locoregional failures occurred each in the 3D CRT (15%) and the IMRT (13%) patients. Grade>or=2 acute gastrointestinal toxicity was found to be similar between the 3D CRT and IMRT patients (61.5% vs 61.2%, respectively) but more treatment breaks were needed (3 vs 0, respectively). The median serum creatinine from before radiotherapy to most recent creatinine was unchanged in the IMRT group (0.80 mg/dL) but increased in the 3D CRT group from 0.80 mg/dL to 1.0 mg/dL (P=.02). The median kidney mean dose was higher in the IMRT versus the 3D CRT group (13.9 Gy vs 11.1 Gy; P=.05). The median kidney V20 was lower for the IMRT versus the 3D CRT group (17.5% vs 22%; P=.17). The median liver mean dose for IMRT and 3D CRT was 13.6 Gy and 18.6 Gy, respectively (P=.19). The median liver V30 was 16.1% and 28%, respectively (P<.001). CONCLUSIONS: Adjuvant chemoradiotherapy was well tolerated. IMRT was found to provide sparing to the liver and possibly renal function. |
| | |
Authors:
|
A Yuriko Minn; Annie Hsu; Trang La; Pamela Kunz; George A Fisher; James M Ford; Jeffrey A Norton; Brendan Visser; Karyn A Goodman; Albert C Koong; Daniel T Chang |
Related Documents
:
|
10974466 - Conformal radiotherapy for paranasal sinus and nasal cavity tumors: three-dimensional t... 15708266 - Preventing radiation retinopathy with hyperfractionation. 19016016 - Prediction of distant metastasis in head neck cancer patients: implications for inducti... 17418966 - Postoperative irradiation of gynecologic malignancies: improving treatment delivery usi... 21358616 - Safety and efficacy of partial hepatectomy for huge (≥10 cm) hepatocellular carcinoma... 15112266 - P53 and p21 expression levels predict organ preservation and survival in invasive bladd... |
Publication Detail:
|
Type: Comparative Study; Evaluation Studies; Journal Article |
Journal Detail:
|
Title: Cancer Volume: 116 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-08-10 Completed Date: 2010-10-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 3943-52 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright (c) 2010 American Cancer Society. |
Affiliation:
|
Department of Radiation Oncology, Stanford University, Stanford, California 94305-5847, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols / administration & dosage* Combined Modality Therapy Female Humans Male Middle Aged Prognosis Radiotherapy, Adjuvant Radiotherapy, Conformal / adverse effects, methods* Radiotherapy, Intensity-Modulated* / adverse effects Stomach Neoplasms / drug therapy, radiotherapy*, surgery Treatment Outcome |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analys...
Next Document: Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.